Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity.
Mougari S, Favède V, Predella C, Reynard O, Durand S, Mazelier M, Pizzioli E, Decimo D, Bovier FT, Lapsley LM, Castagna C, Lieberman NAP, Noel G, Mathieu C, Malissen B, Briese T, Greninger AL, Alabi CA, Dorrello NV, Marot S, Marcelin AG, Zarubica A, Moscona A, Porotto M, Horvat B.
Mougari S, et al. Among authors: noel g.
Commun Biol. 2025 Jan 15;8(1):57. doi: 10.1038/s42003-025-07491-4.
Commun Biol. 2025.
PMID: 39814955
Free PMC article.